FDA rejects China's lung cancer drug ivonescimab
The US FDA rejected Akeso's cancer drug ivonescimab. Akeso shares fell as much as 31.8% in Hong Kong. The drug had become a symbol of China's rise in drug development.
Why it matters
The decision is a setback for Chinese drugmakers seeking US approval.
Background
Akeso is a Hong Kong-listed Chinese biotech company.
The story so far
- US FDA rejects China lung cancer drug
- FDA rejects China's lung cancer drug ivonescimab
Sources
- South China Morning Post ↗Nov 16, 12:00 AM ET
- The Straits Times ↗Nov 15, 7:57 PM ET
This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.